On this page
Polygenic hypercholesterolaemia
Also known as Polygenic high cholesterol · High cholesterol · Hypercholesterolaemia
Most people with high LDL cholesterol do not have a single high-risk gene fault. Instead, they have inherited a larger-than-average number of common DNA variants, each nudging cholesterol up by a tiny amount. Added together across many genes, these small effects can lift LDL into the range that increases heart-disease risk over a lifetime.
Available at Jeen Health
Clinical tests that include this
Overview
Polygenic hypercholesterolaemia describes persistently raised LDL cholesterol that results from the combined action of many common gene variants, rather than from a single inherited mutation. It is the most common genetic basis for high LDL cholesterol in the population. Raised cholesterol overall is very common in the UK: surveys suggest around half of adults have a total cholesterol at or above recommended levels, and high LDL is a major contributor to the burden of heart attacks and strokes. Polygenic risk sits on a continuous spectrum, so there is no sharp line between "affected" and "unaffected" - people simply carry more or fewer cholesterol-raising variants. Lifestyle, diet, weight, other health conditions and age all interact with this genetic background. Because the cause is spread across many genes of small effect, polygenic hypercholesterolaemia is usually identified through a cholesterol blood test and overall cardiovascular risk assessment, not through a single diagnostic gene result.
Symptoms & clinical features
Polygenic hypercholesterolaemia usually causes no symptoms at all. Raised LDL cholesterol is silent and is typically picked up on a routine blood test rather than because a person feels unwell. The main consequence develops slowly over years: cholesterol contributes to fatty build-up in artery walls (atherosclerosis), which can eventually lead to angina, heart attack, stroke or peripheral arterial disease. Visible signs that can occur with very high cholesterol - such as tendon thickening, fatty lumps around the eyes (xanthelasma) or a pale ring around the cornea - are more typical of severe familial (monogenic) forms and are uncommon with polygenic cholesterol. Importantly, having a high polygenic risk does not change how raised cholesterol or heart disease present; it influences how likely they are, not their nature.
Video: Genetics 101
Affected organs
The condition primarily affects the cardiovascular system. Raised LDL cholesterol acts on the walls of arteries throughout the body, where it contributes to atherosclerotic plaque. Over time this most often involves the coronary arteries supplying the heart, the arteries supplying the brain (raising stroke risk) and the peripheral arteries, particularly in the legs. The liver, which clears LDL from the blood, is central to how cholesterol levels are set.
Risks & severity
A polygenic risk score is usually expressed as a percentile (for example, top 10 per cent of the population) or as a relative risk compared with average. Being in a high percentile indicates a greater genetic push toward raised LDL and, over time, cardiovascular disease - but it describes probability across groups, not certainty for an individual. Many people with high scores never develop a problem, and some with low scores still do, because lifestyle, other conditions and chance all contribute. Crucially, the predictive performance of polygenic scores varies by condition and, importantly, by genetic ancestry: most scores were developed largely in European-ancestry populations and tend to be less accurate in people of other backgrounds. Scores should therefore be interpreted as one input among several.
Genetic causes
Polygenic hypercholesterolaemia reflects common-variant architecture: dozens to hundreds of frequent DNA changes, each shifting LDL cholesterol by only a small amount and individually explaining just a tiny fraction of the variation between people, add together to set a person's baseline. Genome-wide association studies have repeatedly implicated variants at or near genes also central to lipid handling, including LDLR (the LDL receptor), APOB, APOE, PCSK9, CELSR2/SORT1/PSRC1, ABCG5/ABCG8, ST3GAL4 and MYLIP, among many others. Validated research scores condense this signal - for example, the well-studied 12-SNP LDL-C score (and a 6-SNP version) draws on variants in CELSR2, APOB, ABCG8, LDLR, APOE and related loci. No single variant is necessary or sufficient; it is the cumulative load that matters. This is fundamentally different from familial hypercholesterolaemia, where one rare, high-impact mutation in LDLR, APOB or PCSK9 raises cholesterol on its own.
Inheritance pattern
Polygenic hypercholesterolaemia is not inherited in a simple Mendelian way. Rather than one gene fault passing through a family with predictable odds, many common variants are scattered across the genome and shuffled independently with each generation. A child inherits a random mix of cholesterol-raising and cholesterol-lowering variants from both parents, so risk falls on a continuous bell-shaped distribution across the population rather than splitting people into clear-cut groups. High cholesterol can still cluster in families - relatives share variants and often environment too - but it does not follow the clean one-in-two pattern seen with familial hypercholesterolaemia. This is why a polygenic risk score is reported as a position on a spectrum, not as a yes/no inherited diagnosis.
Diagnosis & testing
A polygenic risk score is a risk estimate, not a diagnosis. It is calculated by counting the cholesterol-raising variants a person carries across many sites in their DNA and weighting each by its known effect, then comparing the total against a reference population to give a percentile. A high score signals an increased genetic tendency toward raised LDL - it does not confirm that cholesterol is currently high, nor diagnose heart disease. The diagnosis of raised cholesterol itself is made clinically, with a blood lipid panel (total, LDL, HDL and non-HDL cholesterol, plus triglycerides). Where familial hypercholesterolaemia is suspected, the NHS uses clinical criteria and targeted genetic testing of LDLR, APOB and PCSK9 - a separate, single-gene test from a polygenic score.
Management & lifestyle
Management for someone with high polygenic risk centres on early detection and steady risk reduction, because the underlying tendency is lifelong. The first step is simply knowing your numbers: a cholesterol blood test, and an overall cardiovascular risk assessment such as QRISK, which the NHS uses to estimate ten-year heart-attack and stroke risk. Lifestyle measures help everyone with raised LDL - a diet lower in saturated fat, more fibre, regular physical activity, stopping smoking, limiting alcohol and maintaining a healthy weight. When LDL stays high or overall cardiovascular risk is sufficient, NICE guidance supports cholesterol-lowering medication, most commonly a statin, with other options (such as ezetimibe or, in selected cases, PCSK9 inhibitors) where needed. A high polygenic score is best used to prompt earlier conversations and closer monitoring with a GP - it complements, and does not replace, standard NHS cholesterol checks and risk assessment.
UK care pathway
The NHS does not screen the general population specifically for polygenic cholesterol risk. Instead, raised cholesterol is picked up through routine care: the NHS Health Check offered to adults aged 40 to 74 in England includes a cholesterol test and cardiovascular risk assessment, and GPs check lipids when clinically indicated. Risk is estimated using tools such as QRISK, and management follows NICE lipid guidance. Where familial hypercholesterolaemia is suspected, there is a separate NHS pathway involving specialist lipid clinics, single-gene testing and cascade testing of relatives.
Frequently asked questions
How is polygenic hypercholesterolaemia different from a single-gene fault like familial hypercholesterolaemia?
Familial hypercholesterolaemia (FH) is caused by one rare, high-impact mutation - usually in LDLR, APOB or PCSK9 - that raises cholesterol substantially on its own and is passed down a family with roughly one-in-two odds. Polygenic hypercholesterolaemia is the opposite picture: no single variant is to blame. Instead, you have inherited a larger-than-average number of common variants, each adding only a tiny amount, that together push LDL up. Polygenic risk sits on a continuous spectrum and is reported as a score, whereas FH is a specific genetic diagnosis. Interestingly, most people clinically diagnosed with FH who have no detectable mutation turn out to have a polygenic cause.
Is a polygenic risk score the same as a diagnosis of high cholesterol?
No. A polygenic risk score estimates your inherited tendency toward raised LDL cholesterol by adding up many common variants in your DNA and comparing the total with a reference population. It is a risk estimate, not a measurement of your actual cholesterol and not a diagnosis of heart disease. You could have a high score but normal cholesterol on a blood test, or a modest score yet raised cholesterol because of diet, weight or other factors. To know your real levels you need a cholesterol blood test, and any decisions about treatment are based on those results alongside your overall cardiovascular risk.
Is polygenic cholesterol risk scoring available on the NHS?
The NHS does not currently offer polygenic risk scoring for cholesterol as part of routine care. What the NHS does provide is cholesterol testing and cardiovascular risk assessment - for example through the NHS Health Check for adults aged 40 to 74 in England, and through GP testing when clinically appropriate - with management guided by NICE. Single-gene genetic testing is reserved for suspected familial hypercholesterolaemia via specialist lipid services. A polygenic score from a private test can be a useful prompt to get your cholesterol checked and discuss your risk with your GP, but it complements rather than replaces NHS assessment.
If I have a high polygenic score, what should I actually do?
Treat it as an early prompt rather than a verdict. The most useful first step is to get your cholesterol checked with a blood test and have your overall cardiovascular risk assessed by your GP. From there, the same proven measures apply that help anyone with raised LDL: a diet lower in saturated fat and higher in fibre, regular activity, stopping smoking, limiting alcohol and keeping to a healthy weight. If your LDL stays high or your overall risk is high enough, your GP may discuss cholesterol-lowering medication such as a statin under NICE guidance. A high score simply argues for paying attention sooner and monitoring more closely over time.
References
- Woods A. High cholesterol (hyperlipidemia). Nursing. 2002. PMID: 12189985
- High Cholesterol. 1994. PMID: 35952022
- Katzmann JL, Laufs U. Why doesn't high cholesterol hurt? Aging. 2019. PMID: 31829976
- Abbott B. Editing cholesterol out of the blood. Communications medicine. 2021. PMID: 35602209
- Ma J, Gong Z, Lu H. Tissue specific role of ABCA1 in lung cholesterol homeostasis under high-cholesterol diet. Frontiers in nutrition. 2025. PMID: 40808841
- Li X, Chen H, Zhang L. 27-hydroxycholesterol linked high cholesterol diet to lung adenocarcinoma metastasis. Oncogene. 2022. PMID: 35379924
- Chen Y, Yin M, Cao X. Pro- and Anti-inflammatory Effects of High Cholesterol Diet on Aged Brain. Aging and disease. 2018. PMID: 29896426
- Mariano C, Alves AC, Medeiros AM. The familial hypercholesterolaemia phenotype: Monogenic familial hypercholesterolaemia, polygenic hypercholesterolaemia and other causes. Clinical genetics. 2020. PMID: 31893465